Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

Core Insights - Helius Medical Technologies, Inc. has received its first reimbursement payment for the PoNS Device from Anthem Blue Cross Blue Shield, marking a significant milestone for the company and multiple sclerosis (MS) patients [1][2] - The reimbursement payment of $15,420 for the PoNS controller and mouthpiece is based on an out-of-network adjusted list price, which is typically 30 to 40% lower than in-network contracted rates, establishing a benchmark for future negotiations with commercial insurance carriers [2] Company Overview - Helius Medical Technologies is a neurotech company focused on addressing neurologic deficits through its Portable Neuromodulation Stimulator (PoNS), which enhances the brain's ability to engage compensatory mechanisms and promote neuroplasticity [3] - The PoNS Device is a non-implantable therapy that delivers neurostimulation via a mouthpiece, primarily used at home alongside physical rehabilitation exercises to improve balance and gait in patients aged 22 and over with MS [4] Product Efficacy - The PoNS Device has demonstrated effectiveness in treating gait and balance deficits, significantly reducing the risk of falls in stroke patients, and is authorized for use in Canada and Australia for various indications related to stroke and traumatic brain injury [5]